# **Accepted Manuscript**

Medical cannabis associated with decreased opiate medication use in retrospective cross-sectional survey of chronic pain patients

Kevin F. Boehnke, Evangelos Litinas, MD, Daniel J. Clauw, MD

PII: \$1526-5900(16)00567-8

DOI: 10.1016/j.jpain.2016.03.002

Reference: YJPAI 3235

To appear in: Journal of Pain

Received Date: 4 December 2015 Revised Date: 23 February 2016

Accepted Date: 7 March 2016

Please cite this article as: Boehnke KF, Litinas E, Clauw DJ, Medical cannabis associated with decreased opiate medication use in retrospective cross-sectional survey of chronic pain patients, *Journal of Pain* (2016), doi: 10.1016/i.jpain.2016.03.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



# Medical cannabis associated with decreased opiate medication use in retrospective cross-sectional survey of chronic pain patients

Running title: Survey of cannabis, chronic pain, and opiates

Kevin F. Boehnke<sup>a</sup>; Evangelos Litinas, MD<sup>b</sup>; Daniel J. Clauw, MD<sup>c,d,\*</sup>

Word count: 2124

#### **Author Affiliations:**

Department of Environmental Health Sciences, School of Public Health, University of Michigan<sup>a</sup>. 1415 Washington Heights, Ann Arbor MI, 48109. (kboehnke@umich.edu).

Om of Medicine b. 112 S. Main Street, Ann Arbor, MI, 48104. (elitinasmd@gmail.com).

Departments of Anesthesiology, Medicine (Rheumatology), and Psychiatry, Medical School, University of Michigan<sup>c</sup>. 1500 E Medical Center Dr, Ann Arbor, MI 48109

Chronic Pain and Fatigue Research Center, Medical School, University of Michigan<sup>d</sup>. 24 Frank Lloyd Wright Dr, Ann Arbor, MI 48105

\*Corresponding author. Daniel J. Clauw, MD. University of Michigan, 24 Frank Lloyd Wright Dr., PO Box 385, Ann Arbor, MI 48106 (<u>dclauw@med.umich.edu</u>). Phone: 734-998-6939. Fax: 734-998-6900

# **Disclosures:**

Dr, Clauw has performed consulting services for and/or served on scientific advisory boards of Pfizer, Lilly, Forest Laboratories, Johnson & Johnson, Purdue Pharma, Nuvo, Cerephex, Tonix, Iroko, Takaeda, Cerephex, IMC, Zynerba, and Samumed. He has received grant support from Pfizer, Forest, Merck, Nuvo, and Cerephex. Dr. Litinas is the Chief Medical Officer at Om of Medicine, a medical cannabis dispensary in Ann Arbor, Michigan. This study received no external funding support.

Manuscript Highlights:

• Cannabis use associated with 64% lower opioid use in chronic pain patients.

• Cannabis use associated with increased quality of life in chronic pain patients.

Cannabis use associated with fewer medication side effects and medications used.

**Abstract** 

Opioids are commonly used to treat patients with chronic pain (CP), though there is little evidence that

they are effective for long term CP treatment. Previous studies reported strong associations between

passage of medical cannabis laws and decrease in opioid overdose statewide. Our aim was to examine

whether using medical cannabis for CP changed individual patterns of opioid use. Using an online

questionnaire, we conducted a cross-sectional retrospective survey of 244 medical cannabis patients with

CP who patronized a medical cannabis dispensary in Michigan between November 2013 and February

2015. Data collected included demographic information, changes in opioid use, quality of life, medication

classes used, and medication side effects before and after initiation of cannabis usage. Among study

participants, medical cannabis use was associated with a 64% decrease in opioid use (n=118), decreased

number and side effects of medications, and an improved quality of life (45%). This study suggests that

many CP patients are essentially substituting medical cannabis for opioids and other medications for CP

treatment, and finding the benefit and side effect profile of cannabis to be greater than these other classes

of medications. More research is needed to validate this finding.

Perspective: This article suggests that using medical cannabis for CP treatment may benefit for some CP

patients. The reported improvement in quality of life, better side effect profile, and decreased opioid use

should be confirmed by rigorous, longitudinal studies that also assess how CP patients use medical

cannabis for pain management.

Keywords: Medical cannabis, opioids, chronic pain, side effects

Introduction

2

Chronic pain (CP) is amongst the most common and expensive medical conditions, affecting over 100 million Americans, and with total direct and indirect costs of up to \$635 billion dollars per year <sup>8</sup>. Despite their high prevalence, treatment of CP conditions is difficult. Treatments for CP conditions often require incremental lifestyle changes (exercise, sleep hygiene, stress reduction) and repeated doctor visits to monitor changes, which is increasingly challenging in the current economic and medical climate <sup>14</sup>. Furthermore, other potentially efficacious therapies (e.g. cognitive behavioral therapy and complementary approaches) are not often covered by insurance. Finally, opioids – one of the most common medication used to treat CP – are ineffective for many types of CP, as well as being addictive and associated with significant morbidity and mortality <sup>1</sup>. Indeed, opioids are the most common prescription drug implicated in overdose deaths, involved in up to 75% of overdoses, and estimated to be responsible for at least 17,000 deaths annually <sup>10</sup>.

Because of problems with the current treatment of pain, many patients and some providers have begun to re-examine the potential role for cannabis or cannabinoids for treating CP. Since there are no synthetic cannabinoids approved for treatment of CP in the US, the most available form of cannabinoids for most patients is cannabis purchased from dispensaries or illegally. Cannabis has been legal in parts of the USA since 1996 for treatment of multiple conditions, including CP <sup>12</sup>. Randomized controlled trials have examined whether cannabis, cannabis extracts, or synthetic cannabinoids are *efficacious* in chronic pain states, with a recent meta-analysis suggesting that there is moderate evidence that some types of chronic pain states may be improved by use of cannabinoids <sup>15</sup>. In contrast, there have been relatively few studies of the *effectiveness* of cannabinoids in real-life settings. A study out of the Netherlands suggested that 53% of registered cannabis users consumed cannabis for enhanced pain control <sup>7</sup> though other studies have described uncertain efficacy for CP treatment <sup>6</sup>. Interestingly, legalization of medical cannabis was associated with a mean 24.8% decrease in opioid overdose deaths in multiple states across the USA <sup>2</sup>. While suggestive that cannabis could act as a replacement or alternative for opioids, this finding was on an ecological level, so changes at an individual level could not be gauged.

In our current study, we surveyed medical cannabis cardholders in Michigan, who must receive a certification from a licensed physician that they have a condition deemed by the statute to justify cannabis use (e.g. chronic pain) to obtain their permit. We hypothesized that many cannabis users were using cannabis for CP reduction and as a substitute for opioids. We further hypothesized that we may find some evidence that cannabis was reported to be more effective for CP that is "centralized" in nature. By centralized in nature, we mean individuals in whom the central nervous system is playing a greater role in pain, which we have previously shown is associated with decreased responsiveness to opioids <sup>3,4,9</sup>. This is plausible since meta-analyses that have examined the efficacy of cannabinoids in neuropathic and centralized pain states have suggested that these compounds are generally efficacious <sup>13,15</sup>, whereas there is far less evidence for efficacy in nociceptive pain states <sup>16</sup>. Thus, we hypothesized that individuals with higher scores on the 2011 Survey Criteria for fibromyalgia - a continuous measure that can be used both to diagnose fibromyalgia as well as to determine the degree of pain centralization in CP states <sup>13</sup> - would show better overall pain relief with cannabis compared to those using cannabis for CP with lower scores on this measure. If this were to be true, then this would provide very preliminary evidence that cannabis might be a more effective treatment of centralized or neuropathic pain states than opioids, a finding in line with recent meta-analyses of the effects of cannabis in randomized controlled trials in various pain conditions 13,15

# **Methods**

Survey distribution was carried out in collaboration with owners of a local medical cannabis dispensary in Ann Arbor, Michigan, who helped recruit registered medical cannabis patients (≥18 years of age) to take the survey through the Qualtrics online survey platform. Study participants were enrolled between November 2013 and February 2015. Participant anonymity was maintained.

The survey contained 46 questions, detailing the medical condition(s) for which cannabis was used, method/frequency of cannabis use, changes in non-cannabis medication use, changes in medication side

effects, quality of life changes since starting cannabis, and demographic information. As part of the survey, all participants completed the 2011 Fibromyalgia Survey Criteria (FM score), which gives a score from 0-31, with 31 indicating the most severe FM pain <sup>16</sup>. This value indicates a participant's FM score at the time of the survey, rather than their FM score prior to initiation of cannabis use. Survey questions of interest are compiled in table 1.

Table 1. Survey Questions Regarding Outcomes and Exposures of Interest

Survey Question	Answer options
In a typical week, how often do you use cannabis?	<ul> <li>Less than once per week</li> <li>One time</li> <li>2-3 times</li> <li>4-6 times</li> <li>Daily</li> </ul>
On a day that you do use cannabis, how often do you use it?	<ul> <li>Less than once</li> <li>1-2 times</li> <li>3-4 times</li> <li>More than 5 times</li> </ul>
When did you start using cannabis for medical purposes? Please give your answer in years.	Descriptive, ranges from 0-50 years
What classes of drugs were you using (check all that apply) before you started using cannabis? (Choose all that apply)  On a scale of 1-10 (with 1 being not at all and 10 being significantly) how much did the side effects of the medications you took before using cannabis affect your ability to do the things you needed to accomplish each day?	<ul> <li>Opioids (such as Vicodin)</li> <li>NSAIDs (such as aspirin)</li> <li>Disease-modifying antirheumatic drugs (DMARDs)</li> <li>Anti-depressants</li> <li>Serotonin-norepinephrine reuptake inhibitors (SNRIs)</li> <li>Selective serotonin reuptake inhibitors (SSRIs)</li> <li>1-10</li> </ul>
On a scale of 1-10 (with 1 being not at all and 10 being significantly) how much do the side effects of the medications you take in combination with cannabis affect your ability to do the things you needed to accomplish each day?	1-10
How has your opioid prescription drug use changed since you started using cannabis? Increase or decrease (%). If your opioid use has increased by 30%, please write +30%. If your opioid use has decreased by 30%, please write in -30%.	-100% through 100%

Are you taking any of the following drugs or drug	Opioids (such as Vicodin)
classes in combination with cannabis? (Choose all that	<ul> <li>NSAIDs (such as aspirin)</li> </ul>
apply)	Disease-modifying antirheumatic
	drugs (DMARDs)
	Anti-depressants
	Serotonin–norepinephrine reuptake
	inhibitors (SNRIs)
	Selective serotonin reuptake inhibitors (SSRIs)

#### **Statistics**

The study population was examined using descriptive statistics. To ensure that no important information was missed by limiting analyses to fully completed questionnaires, sensitivity analyses were performed on the entire set of questionnaires, questionnaires that were ≥60% complete, ≥80% complete, and those that were fully completed. (Table 2). There were very little differences between the outcomes, so analysis was limited to those questionnaires that were fully completed. FM scores of participants were stratified into quartiles to examine whether degree of pain centralization was associated with outcomes of interest. Relationships between FM score quartile, opioid use change, quality of life change, when the study participant began using cannabis, and medication side effects were examined using Pearson's correlation test. Student t-tests were used to examine whether cannabis use affected the number of medication classes (e.g. opioids, non-steroidal anti-inflammatory drugs, selective serotonin uptake inhibitor, disease modifying anti-rheumatic drugs, etc.) taken, medication side effects, and and paired T-tests were used to evaluate changes in these variables before and after initiation of cannabis. Analysis of variance tests were used to examine whether changes in quality of life or opioid use were associated with FM score.

All analyses were carried out in R Studio version 0.98.1103 (R-Tools Technology Inc.).

#### Ethics statement

This study was exempted from Institutional Review Board (IRB) oversight under protocol HUM00079724 at the University of Michigan. Participants freely consented to participate in the study, and were able to drop out at any time.

# Results

Of the 374 participants in the study, 244 of participants used cannabis to treat chronic pain. Sensitivity analyses showed that exclusion of incomplete questionnaires did not have a significant effect on outcomes (table 2), so only the complete questionnaires of participants with chronic pain were used (n=185).

Table 2. Sensitivity Analysis Among Participant Questionnaires with Chronic Pain

	Entire set of questionnaires N=244	Questionnaires that were ≥60% completed N=192	Questionnaire that were ≥80% completed N=186	Questionnaires that were fully completed* N=185
FM score	9.23 (5.52)	9.28 (5.54)	9.15 (5.40)	9.16 (5.42)
Opioid use change	-63% (46%)	-63% (47%)	-64% (44%)	<u>-64% (45%)</u>
Degree to which side effects of medication affect daily function (before using medical cannabis). Scale from 1-10	6.44 (2.91)	6.42 (2.91)	6.46 (2.89)	6.51 (2.88)
Degree to which side effects of medication affect daily function (after using medical cannabis). Scale from 1-10	2.77 (2.35)	2.78 (2.36)	2.78 (2.38)	2.79 (2.39)
Number of medication classes used (pre-cannabis)	2.35 (1.43)	2.34 (1.44)	2.36 (1.44)	2.38 (1.44)
Number of medication classes used (post-cannabis)	1.82 (0.94)	1.84 (0.95)	1.83 (0.95)	1.81 (0.95)
Quality of life change	45% (28%)	45% (28%)	45% (29%)	45% (29%)

<sup>\*</sup>Used only fully completed questionnaires for final analyses.

Demographic information is summarized in table 3. Of note, the majority of participants (78.9%) smoked cannabis daily. Outcomes (opioid use change, quality of life change, number of medications, and medication side effects) in the total chronic pain population and in FM score quartiles are summarized in table 4.

Table 3: Demographic Characteristics of Study Population

Variable	N (185)
Sex	
Male	118 (64%)
Female	65 (35%)
Refuse to answer	2 (1%)
Age	
18-25	32 (17%)
26-35	40 (22%)
36-45	32 (17%)
46-55	25 (14%)
56-65	46 (25%)
66-75	9 (5%)
Refuse to answer	1 (0.5%)
Weekly cannabis use	
<1 time	1 (0.5%)
2-3 times	16 (9%)
4-6 times	22 (12%)
Daily	146 (79%)
Daily cannabis use	
1 time	22 (12%)
2 times	47 (25%)
3-4 times	77 (42%)
5+ times	38 (20%)
Refuse to answer	1 (0.5%)
Opioid Use Before Cannabis	
Yes	119 (64%)*
No	66 (36%)
Change and a state of	
Chronic pain status	105
Yes	185

<sup>\*</sup>One participant chose not to respond to the question about change in opioid use.

Table 4: Outcomes of Interest in the Study Population

	Chronic Pain	FM Score Quartile	FM Score Quartile	FM Score Quartile	FM Score Quartile
	(n=185)	1 (n=56)	2 (n=42)	3 (n=43)	4 (n=44)
FM score	9.16	3.61	7.12	10.40	16.95
7	(5.42)	(1.27)	(0.74)	(1.22)	(3.70)
	n=185	n=56	n=42	n=43	n=44
Opioid use change (-100% to	-64%	-79%	-74%	-63%	-48%
100%)	(45%)	(32%)	(40%)	(39%)	(54%)
	n=118	n=28	n=22	n=30	n=38
Degree to which side effects of	6.51	5.89	5.7 (3.16)	7.06	7.22
medication affect daily function	(2.88)	(3.29)	n=27	(2.39)	(2.45)
before using medical cannabis.	n=136	n=38		n=35	n=36

Scale from 1 (no effect) to 10 (significant effect)					
Degree to which side effects of	2.79	1.92 (1.96)	1.70	3.60 (2.76)	3.72
medication affect daily function after using medical cannabis.	(2.39) n=136	n=38	(1.29) n=27	n=35	(2.46) n=36
Scale from 1 (no effect) to 10 (significant effect)					
Change in medication side effects	-3.72	-3.97	-4.00	-3.46	-3.50
after initiation of cannabis	(3.42) n=136	(3.72) n=38	(3.25) n=27	(3.31) n=35	(3.43) n=36
Number of medication classes	2.38	1.96	1.88	2.40	3.3
used (pre-cannabis)	(1.44)	(1.36)	(1.10)	(1.35)	(1.46)
	n=184	n=56	n=41	n=43	n=44
Number of medication classes	1.81	1.46	1.54	1.95	2.39
used (post-cannabis)	(0.95)	(0.69)	(0.67)	(1.11)	(0.99)
	n=184	n=56	n=41	n=43	n=44
Change in quality of Life (-100%	+45 (29%)	+54%	+43%	+44%	+38%
to 100%)	n=180	(31%)	(26%)	(28%)	(27%)
		n=54	n=41	n=42	n=43

NOTE. Fibromyalgia (FM) score and quartiles, change in opioid use, quality of life, side effects of medications pre- and post-cannabis, and number of medication classes used pre- and post-cannabis. All quantities reported as mean (standard deviation).

Effects of cannabis on opioid use

The mean change in self-reported opioid use among all respondents answering this question was -64%. Interestingly, in contrast to our hypothesis, the reduction of opioid use was the least drastic in the highest FM score quartile (-48%), which was significantly different from the lowest FM score quartile (-79%, p=0.03) but not the 2<sup>nd</sup> and 3<sup>rd</sup> (-74% and -63%, p=0.14 and 0.59, respectively).

Effects of cannabis on number of medication classes used and side effects of medications

The number of medication classes used after initiation of cannabis was (1 + reported number) to account for cannabis use. Pre and post medications used are reported in Table 5. Although we focus in this manuscript on opioid dosage reductions since this has become a major public health problem in the US, there were comparable reductions in self-reported usage of many other classes of analgesic drugs. The mean number of medications classes used decreased significantly in all respondents before and after cannabis use (2.38 vs. 1.81, respectively, p<0.001).

Table 5: Medication Classes Used Before and After Initiation of Cannabis Among Study Population

Medication type	Use before initiation of cannabis (n/N)	Use after initiation of cannabis (n/N)
Opioids	119/184 (65%)	33/184 (18%)
NSAIDs	115/184 (62%)	38/184 (21%)
Disease-modifying antirheumatic drugs (DMARDs)	15/184 (8%)	3/184 (2%)
Anti-depressants	72/184 (39%)	25/184 (14%)
Serotonin-norepinephrine reuptake inhibitors (SNRIs)	13/184 (7%)	3/184 (2%)
Selective serotonin reuptake inhibitors (SSRIs)	34/184 (18%)	8/184 (4%)
Other	69/184 (38%)	40/184 (22%)

NOTE. Study participants reported using fewer medication classes of all categories after initiation of cannabis.

Although we did not find our hypothesized findings that individuals with more centralized pain (e.g. with a more fibromyalgia-like phenotype) reported increased effectiveness of cannabis, we did find that the degree of pain centralization predicted differential medication usage both before and after cannabis usage. Participants in the 4<sup>th</sup> FM score quartile used a significantly higher number of medication classes than those in the 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> quartile before initiation of cannabis (p<0.001, p<0.001, p=0.004, respectively). After initiation of cannabis use, participants in the 4<sup>th</sup> FM score quartile continued to use a significantly higher number of medication classes compared to those in the other quartiles (p<0.001, p<0.001, p=0.068 in the 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> quartiles, respectively). Side effects of medication on everyday functioning dropped substantially after cannabis use (6.51 vs. 2.79, p<0.001). There were no differences in the change in medication side effects among FM score quartiles (p=0.86).

### **Discussion**

Our primary study hypothesis that patients would self-report that they derived more pain relief from cannabis if they had more centralized pain was not supported. In fact, patients with lower pain centralization levels noted the best improvements in quality of life, as well as the largest reductions in opioid usage. However, this study did yield several significant findings. Overall, since the initiation of medical cannabis use, chronic pain patients reported significant decreases in medication side effects that affected their daily functioning (including opioids), decreases in total number of medications being taken, and improvements in quality of life. Reported reduction in opioid use and decreased medication side

effects were significantly correlated (r=0.37, p=0.0002), indicating a potential health benefit of replacing opioids with cannabis. This "opioid-sparing" effect is consistent with the ecological study by Bachhuber et al <sup>2</sup>, and hints to potential synergistic effects between cannabis and opioids for reduction of severe CP. Indeed, a recent study in Australia found that people with CP had better pain reduction when they combined opioids and cannabis <sup>5</sup>.

#### Limitations

While suggestive, the cross-sectional study design limits inference from our data, since our outcomes of interest (changes in quality of life, opioid use, side effects of medication, and number of medications) were measured with potentially unreliable recall data. Indeed, some study participants had been using cannabis for medical purposes for quite some time (median of 4 years). FM scores were measured at the time of the survey, so we were unable to know participant's baseline FM score before they started using cannabis, potentially biasing the data. Furthermore, our results may not be representative of the general population, since we only surveyed patrons of a medical cannabis dispensary. Finally, with the recent attention to opioid overuse and overdose, we considered the possibility that physicians would reduce the number of opioid prescriptions, which could have happened concurrently with our study. This could provide an explanation for the drastic lowering of opioids that we report. However, the Michigan Department of Community Health and the Michigan Automated Prescription System (MAPS) showed consistent increases in the number opioid prescriptions written from 2007-2014 (7.7 million in 2007 to 9.7 million in 2014) and in the number of opioid units prescribed from 2011-2014 (over 620 million units total in 2011 to almost 677 million in 2014) 11,17. Though we do not know if the statewide trends apply to our study, our observed lowered opioid use is not consistent with these trends, suggesting that it may be due to other factors (including the use of cannabis).

Future directions and Conclusions

Future studies can address these issues by using longitudinal study designs that recruit participants naïve to cannabis and measure their pain levels before and after using cannabis. This would make the results more robust by taking into account temporality, and resolve issues of selection bias in our current study. We plan to continue recruiting participants for this study to validate the robustness of our results in a larger population. Since cannabis is a Schedule I drug, much of the literature surrounding its efficacy as medication is anecdotal and/or not peer reviewed. While we caution against using this study to change clinical practice towards cannabis, this study provides intriguing hints of the value of cannabis, both as an effective pain medication and as an effective agent against opioid overuse and overdose.

# **Acknowledgements**

We thank Mark Passerini and Keith Lambert at Om of Medicine for their help on this project, and the Om of Medicine staff for their help in administering the survey.

# References

- 1. Arnold LM, Clauw DJ, Dunegan LJ, Turk DC: A framework for fibromyalgia management for primary care providers. Mayo Clin Proc [Internet] 87:488–96, 2012 [cited 2015 Sep 24]. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3498162&tool=pmcentrez&rendertype =abstract
- 2. Bachhuber MA, Salone B, Cunningham CO, Barry CL: Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010. JAMA Intern Med 19104:1–6, 2014.
- 3. Brummett C, Janda A, Schueller C, Tsodikov A, Morris M, Williams D, Clauw D: Survey Criteria for Fibromyalgia Independently Predict Increased Postoperative Opioid Consumption after Lower-extremity Joint Arthroplasty. Anesthesiology [Internet] 119:1434–43, 2013. Available from: http://journals.lww.com/anesthesiology/Abstract/2013/12000/Survey\_Criteria\_for\_Fibromyalgia\_I ndependently.30.aspx
- 4. Clauw DJ: Fibromyalgia: a clinical review. Jama [Internet] 311:1547–55, 2014. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2014.3266
- 5. Degenhardt L, Lintzeris N, Campbell G, Bruno R, Cohen M, Farrell M, Hall WD: Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug Alcohol Depend [Internet] Elsevier Ireland Ltd; 147:144–50, 2015. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0376871614019759
- 6. Farrell M, Buchbinder R, Hall W: Should doctors prescribe cannabinoids? BMJ [Internet] 348:g2737, 2014. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24760158
- 7. Hazekamp A, Heerdink ER: The prevalence and incidence of medicinal cannabis on prescription

- in the Netherlands. Eur J Clin Pharmacol 69:1575-80, 2013.
- 8. Institute of medicine (US). Committee on Advancing Pain Research, Care and E: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011.
- 9. Janda AM, As-Sanie S, Rajala B, Tsodikov A, Moser SE, Clauw DJ, Brummett CM: Fibromyalgia survey criteria are associated with increased postoperative opioid consumption in women undergoing hysterectomy. Anesthesiology [Internet] 122:1103–11, 2015 [cited 2015 Sep 24]. Available from: http://europepmc.org/abstract/med/25768860
- 10. Jones CM, Mack KA, Paulozzi LJ: Pharmaceutical overdose deaths, United States, 2010. JAMA [Internet] American Medical Association; 309:657–9, 2013 [cited 2015 Apr 25]. Available from: http://jama.jamanetwork.com/article.aspx?articleid=1653518
- 11. LARA: MAPS Statistics [Internet]. 2015 [cited 2015 Nov 5]. Available from: http://www.michigan.gov/lara/0,4601,7-154-72600\_72603\_55478\_55484---,00.html
- 12. Leung L: Cannabis and its derivatives: review of medical use. J Am Board Fam Med [Internet] American Board of Family Medicine; 24:452–62, 2011 [cited 2015 Sep 22]. Available from: http://www.jabfm.org/content/24/4/452.full
- 13. Lynch ME, Campbell F: Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol 72:735–44, 2011.
- 14. Phillips K, Clauw DJ: Central pain mechanisms in the rheumatic diseases: Future directions. Arthritis Rheum 65:291–302, 2013.
- 15. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez A V., Keurentjes JC, Lang S, Misso K, Ryder S, Schmidlkofer S, Westwood M, Kleijnen J: Cannabinoids for Medical Use. Jama [Internet] 313:2456–73, 2015. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.6358
- 16. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, Mease P, Russell AS, Russell IJ, Winfield JB: Fibromyalgia criteria and severity scales for clinical and epidemiological studies: A modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 38:1113–22, 2011.
- 17. Zimmer M, Lyon N: 2014: The "State" of Pain in Michigan. 630:1–16, 2014.